For non-US healthcare professionals: Get information about ZOMETA and its product characteristics.
This is an international site for Zometa® (zoledronic acid) and is intended for Health Care Professionals outside the U.S. The information on the site is not country-specific, and may contain information that is outside the approved indications in the country in which you are located. Please contact your local Novartis representative for the latest information specific to your country.
ZOMETA is approved for use in the following countries: Albania, Argentina, Aruba, Australia, Austria, Azerbaijan, Bahrain, Bangladesh, Belarus, Belgium, Bosnia-Herzegovina, Brazil, Bulgaria, Cambodia, Canada, Chile, Colombia, Costa Rica, Croatia, Cuba, Curacao, Cyprus, Czech Republic, Denmark, Dominican Republic, Ecuador, El Salvador, Estonia, Finland, France, Georgia, Germany, Greece, Guatemala, Honduras, Hong Kong, Hungary, Iceland, India, Indonesia, Ireland, Israel, Italy, Jamaica, Japan, Jordan, Kazakhstan, Korea, Kuwait, Latvia, Lebanon, Lithuania, Luxembourg, Macedonia, Malaysia, Malta, Mexico, Moldova, New Zealand, Nicaragua, Norway, Oman, Pakistan, Panama, Peru, Philippines, Poland, Portugal, Qatar, Republic Srpska, Romania, Russia, Saudi Arabia, Serbia, Singapore, Slovak Republic, Slovenia, South Africa, Spain, Sri Lanka, Sweden, Switzerland, Syria, Taiwan, Thailand, The Netherlands, Trinidad and Tobago, Turkey, Ukraine, United Arab Emirates, United Kingdom, United States, Uruguay, Uzbekistan, Venezuela.
Below is a list of the countries that host a ZOMETA website based on local label and in local language. They are intended for Healthcare Professional (HCPs) only. Click on any of the links to be redirected to that country-level website.
ZOMETA International Website
This website is intended for Healthcare Professionals (HCPs) outside the U.S. The information on this website is not country specific and may contain information that is outside the approved indication in the country in which you are located. Please contact your local representative for local prescribing information via www.novartisoncology.com/contactus.
IMPORTANT: The information on this website is based on the European Summary of Product Characteristics (EUSmPC)
Patients with advanced bladder cancer are living longer, but skeletal complications remain a serious threat1,2
Bone metastases are a major concern for patients with advanced bladder cancer2,3
40% of patients with advanced bladder cancer develop bone metastases,* which may lead to bone complications or skeletal-related events (SREs)3†
A clinical trial demonstrated that without treatment with a bone-targeted agent2
90% of patients with bladder cancer and bone metastases experienced an SRE within 1 year
SRE frequency was approximately every 6 months
*Incidence at autopsy. †SREs are generally defined as pathological fractures, spinal cord compression, radiation or surgery to bone, or tumour-induced hypercalcaemia.4
As new treatments extend survival, the threat of SREs increases1,2
‡Median time to first SRE for patients treated with placebo in a clinical trial. §Median overall survival for patients treated with gemcitabine and cisplatin.
References: 1. von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;17:3068-3077. 2. Zaghloul MS, Boutrus R, El-Hossieny H, Kader YA, El-Attar I, Nazmy M. A prospective, randomized, placebo-controlled trial of zoledronic acid in bony metastatic bladder cancer. Int J Clin Oncol. 2010;15:382-389. 3. Coleman RE. Metastatic bone disease: clinical features, pathophysiology and treatment strategies. Cancer Treatment Rev. 2001;27:165-176. 4. ZOMETA Summary of Product Characteristics. Novartis Pharma AG.
Disclaimer: This is an international website for ZOMETA® (zoledronic acid) and is intended for healthcare professionals outside the US. If you are a US resident, please click on the US Residents link at the top of this page. The information on this site is not country-specific and may contain information that is outside the approved indications in the country in which you are located.